ReviewZeitschrift fur Rheumatologie2025
[Update on the treatment of rheumatic immune-related adverse events under immune checkpoint inhibition].
Review in Zeitschrift fur Rheumatologie, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors (ICI) lead to immune-mediated toxicity, so-called immune-related adverse events (irAE) in nearly all patients treated. These also include exacerbations of pre-existing autoimmune diseases. This update focuses on the evidence for and the management of rheumatic irAEs, which occur in patients with an underlying rheumatic disease. Despite the existing gaps in evidence and knowledge, it is highlighted that in rheumatological patients a thorough interdisciplinary consideration and planning of the baseline and irAE medications can be decisive for the outcome. From the current literature and also own experience in the MalheuR project, it can be derived that in general ICI treatment can be carried out even in patients with pre-existing rheumatic diseases with acceptable safety and good efficacy. The present update and the advisory service of the MalheuR project aim to increase the number of patients with pre-existing rheumatological diseases who receive the possibility of a (successful) ICI treatment in an interdisciplinary setting.
Indexed as
Identifiers
40553161What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.